Kathrin Jobski1, Andres Luque Ramos1, Katinka Albrecht2, Falk Hoffmann1. 1. Department of Health Services Research, Carl von Ossietzky University Oldenburg, Oldenburg, Germany. 2. Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.
Abstract
PURPOSE: Pain and depressive symptoms are common in patients with rheumatoid arthritis (RA). Information on the prevalence and treatment of both conditions in German RA patients is scarce. METHODS: Using data from a nationwide statutory health insurance fund (BARMER GEK), 6193 RA patients aged 18 to 79 years were provided with a questionnaire covering a variety of items such as demographics, medical condition and quality of life in 2015. Pain caused by the joint disorder (11-point scale) was classified as none existent/mild, moderate or severe. Depressive symptoms were determined using the World Health Organization's five-item Well-being Index and categorized as none existent, mild or moderate/severe. Another item covered additional use of over-the-counter drugs. Data were linked to dispensation records. RESULTS: A total of 3140 RA patients were included. Median age was 66 years (79% female). About 70% of patients were classified as having moderate or severe pain. Depressive symptoms were found in 52% and were far more common among patients with higher pain levels. Analgesic treatment ranged from 45% to 76% (non-opioid analgesics) and from 6% to 33% (opioids) in patients with no/mild pain and those reporting severe pain, respectively. In patients reporting moderate or severe pain, substantially higher prevalences of opioid use were observed among those with depressive symptoms. Depending on depressive symptoms, antidepressant use ranged from 7% to 37%. Overall, over-the-counter drug use varied between 30% and 59%. CONCLUSIONS: Pain and depressive symptoms are highly prevalent in German RA patients, often present together and influence each other's treatment.
PURPOSE:Pain and depressive symptoms are common in patients with rheumatoid arthritis (RA). Information on the prevalence and treatment of both conditions in German RApatients is scarce. METHODS: Using data from a nationwide statutory health insurance fund (BARMER GEK), 6193 RApatients aged 18 to 79 years were provided with a questionnaire covering a variety of items such as demographics, medical condition and quality of life in 2015. Pain caused by the joint disorder (11-point scale) was classified as none existent/mild, moderate or severe. Depressive symptoms were determined using the World Health Organization's five-item Well-being Index and categorized as none existent, mild or moderate/severe. Another item covered additional use of over-the-counter drugs. Data were linked to dispensation records. RESULTS: A total of 3140 RApatients were included. Median age was 66 years (79% female). About 70% of patients were classified as having moderate or severe pain. Depressive symptoms were found in 52% and were far more common among patients with higher pain levels. Analgesic treatment ranged from 45% to 76% (non-opioid analgesics) and from 6% to 33% (opioids) in patients with no/mild pain and those reporting severe pain, respectively. In patients reporting moderate or severe pain, substantially higher prevalences of opioid use were observed among those with depressive symptoms. Depending on depressive symptoms, antidepressant use ranged from 7% to 37%. Overall, over-the-counter drug use varied between 30% and 59%. CONCLUSIONS:Pain and depressive symptoms are highly prevalent in German RApatients, often present together and influence each other's treatment.
Authors: Ian C Scott; James Bailey; Christopher R White; Christian D Mallen; Sara Muller Journal: Rheumatology (Oxford) Date: 2022-08-03 Impact factor: 7.046
Authors: Germán Morís; Libby Wood; Roberto FernáNdez-Torrón; José Andrés González Coraspe; Chris Turner; David Hilton-Jones; Fiona Norwood; Tracey Willis; Matt Parton; Mark Rogers; Simon Hammans; Mark Roberts; Elizabeth Househam; Maggie Williams; Hanns Lochmüller; Teresinha Evangelista Journal: Muscle Nerve Date: 2017-11-07 Impact factor: 3.217